Skip to content

Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection

Prospective, Multicenter, Open-Label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak After Lung Resection in High-risk Patients, Applying HEMOPATCH®

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02491671
Enrollment
260
Registered
2015-07-08
Start date
2015-11-24
Completion date
2019-06-30
Last updated
2021-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolonged Air Leak, Lung Resection

Keywords

Prevention PAL Prolonged Air Leak (PAL), Lung Resection, Thoracic Surgery, Post-operative Thoracic Air Leak

Brief summary

The effectiveness of tissue sealants to prevent Prolonged Air Leak (PAL) after lung resection procedures remains unproved. The investigators hypothesize that one of the main reasons for that is the heterogeneity of previously studied populations. Since currently the risk of postoperative PAL can be scored with a reasonable accuracy, the aim of this research is to investigate the effect of routine application of a novel tissue sealant in patients selected on the basis of a high risk of PAL estimated before surgery.

Interventions

Sponsors

Instituto de Investigación Biomédica de Salamanca
CollaboratorOTHER
Baxter Healthcare Corporation
CollaboratorINDUSTRY
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Scheduled anatomical lung resection indicated for any non-infectious disease (excluding Pneumonectomy) * Patients classified in class D according estimated risk of PAL * Age between 18 and 80 years

Exclusion criteria

* Those patients that according to Investigator assessment are not going to tolerate the procedure * Clinical and anesthetic criteria that contraindicate surgery * Severe uncontrolled illness * Pregnancy * Patients that are under Investigational New Drug treatment or have participated in study with a investigational drug (authorized or not) in 30 days before randomization. * Lack of Informed Consent or patient refusal * Postsurgery mechanical ventilation or repeated surgery in follow-up month.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Prolonged Air Leak (PAL)From day of surgery to the fifth postoperative dayPrevalence of Prolonged Air Leak (PAL) measured as binary variable (YES/NO) and recorded, from day of surgery to the fifth postoperative day, in the study questionnaire. The occurrence of the outcome will be recorded if air leak exists 5 days or more after surgery

Secondary

MeasureTime frameDescription
Duration of Air LeaksCheck everyday from day of surgery up to 38 days post-operative at maximumMeasured as continuous variable (days) and recorded, from day of surgery to the day of withdraw the chest tube. (standardized criteria for pulling out chest drainage/s will be agreed among investigators)
Number of Participants With at Least One Chest Tube ReinsertionFrom day of surgery up to 30 days thereafterRate of patients needing postoperative reinsertion of chest drainages due to symptomatic pneumothorax. Following daily during hospital stay and pone follow-up until 30th day post-operative.
Number of Participants With One or More Readmission30 days post-operativeRate of readmissions due to relapsing pneumothorax (follow-up 30 days)

Countries

Spain

Participant flow

Participants by arm

ArmCount
Experimental Group
Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis. Hemopatch standard preventive measures
118
Control Group
Control group: The standard preventive measures will be followed in each center, including reinforcement of sutures, pleural tents, suturing pericardial or subcutaneous fat standard preventive measures
118
Total236

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event68
Overall StudyDeath02
Overall StudyUse of sealants other than Hemopatch53

Baseline characteristics

CharacteristicExperimental GroupControl GroupTotal
Age, Continuous70.77 years70.76 years70.77 years
American Society of Anesthesiologists (ASA) classification
ASA 2
54 Participants51 Participants105 Participants
American Society of Anesthesiologists (ASA) classification
ASA 3
62 Participants65 Participants127 Participants
American Society of Anesthesiologists (ASA) classification
ASA 4
2 Participants2 Participants4 Participants
Body Mass Index24.5 kg/m^224.27 kg/m^224.4 kg/m^2
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Spain
118 participants118 participants236 participants
Sex: Female, Male
Female
25 Participants27 Participants52 Participants
Sex: Female, Male
Male
93 Participants91 Participants184 Participants
Type of Surgery
Bilobectomy
5 Participants7 Participants12 Participants
Type of Surgery
Lobectomy
106 Participants107 Participants213 Participants
Type of Surgery
Segmentectomy
7 Participants4 Participants11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1182 / 118
other
Total, other adverse events
0 / 1180 / 118
serious
Total, serious adverse events
3 / 1187 / 118

Outcome results

Primary

Number of Participants With Prolonged Air Leak (PAL)

Prevalence of Prolonged Air Leak (PAL) measured as binary variable (YES/NO) and recorded, from day of surgery to the fifth postoperative day, in the study questionnaire. The occurrence of the outcome will be recorded if air leak exists 5 days or more after surgery

Time frame: From day of surgery to the fifth postoperative day

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Experimental GroupNumber of Participants With Prolonged Air Leak (PAL)33 Participants
Control GroupNumber of Participants With Prolonged Air Leak (PAL)24 Participants
p-value: 0.17195% CI: [0.891, 1.583]Chi-squared
Secondary

Duration of Air Leaks

Measured as continuous variable (days) and recorded, from day of surgery to the day of withdraw the chest tube. (standardized criteria for pulling out chest drainage/s will be agreed among investigators)

Time frame: Check everyday from day of surgery up to 38 days post-operative at maximum

ArmMeasureValue (MEAN)
Experimental GroupDuration of Air Leaks1 days
Control GroupDuration of Air Leaks1 days
p-value: >0.05Wilcoxon (Mann-Whitney)
Secondary

Number of Participants With at Least One Chest Tube Reinsertion

Rate of patients needing postoperative reinsertion of chest drainages due to symptomatic pneumothorax. Following daily during hospital stay and pone follow-up until 30th day post-operative.

Time frame: From day of surgery up to 30 days thereafter

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Experimental GroupNumber of Participants With at Least One Chest Tube Reinsertion3 Participants
Control GroupNumber of Participants With at Least One Chest Tube Reinsertion6 Participants
p-value: 0.30795% CI: [0.657, 1.879]Chi-squared
Secondary

Number of Participants With One or More Readmission

Rate of readmissions due to relapsing pneumothorax (follow-up 30 days)

Time frame: 30 days post-operative

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Experimental GroupNumber of Participants With One or More Readmission0 Participants
Control GroupNumber of Participants With One or More Readmission0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026